Carlsmed 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Carlsmed reported 3rd quarter 2026 revenue of $21.6 million, up 65% from $13.1 million in the 3rd quarter of 2025.
- Procedure volume grew 76% year over year, and the trained surgeon user base grew more than 60% year over year.
- Gross margin was 77.3%, compared with 75.9% in the 3rd quarter of 2025, an expansion of approximately 140 basis points.
- Adjusted EBITDA was negative $7.3 million, compared with negative $8.2 million in the 3rd quarter of 2025; adjusted net loss per share was negative $0.34.
- Cash, restricted cash, and investments totaled $80.3 million as of September 30th, 2026, and quarterly cash burn was $9 million; term loan debt was $15.6 million under a $50 million debt facility maturing in October 2030.
- Carlsmed launched its Aprivo posterior bilateral procedure in mid-October and said its lumbar franchise represented 88% of 3rd quarter revenue, while cervical represented 12%.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed Third Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the conference over to your first speaker today, Stephanie Zhadkevich, Investor Relations. Please go ahead, Stephanie. Thank you, operator.
Welcome to Carlsmed's Third Quarter 2026 Earnings Call. Joining me today are Mike Cordonnier, Chairman and Chief Executive Officer, and Rich Heppenstall, Chief Financial Officer. Before we begin, I would like to caution you that comments made during this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the market in which Carlsmed operates, the potential of Carlsmed's current and future product offerings to improve patient outcomes, trends, expectations, and demand for Carlsmed's products, expectations with respect to reimbursement, statements about the company's clinical data, surgeon and customer adoption, procedure volume and utilization, the timing of Carlsmed's future product launches and its planned multicenter cervical registry, the ability of Carlsmed to scale, and Carlsmed's expected financial performance, growth prospects, and position in the market. Any forward-looking statement made during this call, including projections for future performance, is based on management's expectations as of today. Carlsmed undertakes no obligation to update these statements except as required by applicable law.
These statements are neither promises nor guarantees and are subject to known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. For more detailed information, please review the cautionary notes in the earnings materials accompanying today's presentation, as well as Carlsmed's filings with the SEC, particularly the risk factors described in Carlsmed's annual report on Form 10-K for the year ended December 31, 2025. I encourage you to review all Carlsmed's filings with the SEC concerning these and other matters. These filings, along with Carlsmed's press release for the third quarter 2026 results, are available on Carlsmed's website at www.carlsmed.com under the Investors section and include additional information about Carlsmed's financial results. Additionally, during today's call, management will discuss certain non-GAAP financial measures, including adjusted EBITDA and adjusted net loss per share.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in today's earnings press release. A recording of today's call will be available on Carlsmed's website by 5:00 P.M. Pacific Time today. Now, I would like to turn the call over to Mike to go over Carlsmed's business highlights.
Thank you, Stephanie, and welcome, everyone. At Carlsmed, our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We aim to accomplish this through our proprietary data and AI-enabled surgeon-in-the-loop personalized surgery platform. The published clinical evidence behind aprevo, which demonstrates meaningful reductions in re-operations, continues to drive strong surgeon adoption, procedure volume, and revenue growth, while our inventory-light, digital-first model lets us scale that growth efficiently. We believe Carlsmed represents the future standard in medical technology, one that is better for patients, surgeons, hospitals, and payers. The third quarter represented strong execution against our long-term strategy as we reach an inflection point in our business. We delivered 65% revenue growth, and we're raising our full-year revenue guidance to between $78 million and $80 million.
We continue to demonstrate operational excellence, consistently delivering aprevo personalized surgery kits in about a week, expanding gross margin, and improving quarterly adjusted EBITDA year-over-year. We broadened our portfolio with the commercial launch of our aprevo lumbar bilateral posterior system in October and are preparing for the full launch of our corra cervical plating system, both of which we expect to be meaningful catalysts in 2027. On reimbursement, the new lumbar MS-DRGs that took effect on October 1st are a significant win that we anticipate will make it easier for hospitals to provide access and adopt aprevo. We announced organizational updates that strengthen our leadership team and prepare Carlsmed for its next phase of scale. As a pure-play personalized surgery company, our technology platform leverages proprietary data assets and foundational AI models to create surgeon-specific 3D surgical plans and translate that to 3D-printed anatomical correction implants.
Published studies involving our closed-loop technology and aprevo personalized fusion procedures have demonstrated predictable outcomes and a meaningful reduction in re-operations. Our underlying technology platform powers the business to run capital-light and drive sustainable, profitable, long-term growth. Commercially, we delivered strong revenue of $21.6 million during the third quarter, representing 65% growth over the prior year. This was driven by rapidly onboarding new surgeons, deepening utilization within our existing customer base, and building upon our 4Q 2025 launch of aprevo Cervical. In the third quarter, our trained surgeon user base grew more than 60% year-over-year, driven by continued strong additions of new surgeons who performed their first aprevo procedure in the quarter, and procedure volume grew 76% year-over-year, with a growing contribution from aprevo Cervical procedures.
As a result of this strong growth in the first nine months of 2026, in combination with our expectations for the fourth quarter, we're raising our full-year 2026 revenue guidance, which Rich will detail shortly. Organizationally, we recently announced management team updates to prepare Carlsmed for the meaningful growth we see ahead. In September, we promoted Jeff Bertolini to Chief Operating Officer. Jeff previously led operational excellence in advanced manufacturing technologies at Carlsmed, where he drove the deployment of advanced technologies throughout our digital production process, and he will lead our operations as we rapidly scale. We also welcomed Rich Heppenstall as Chief Financial Officer. Rich brings deep public company medtech finance experience, most recently as CFO of ZimVie, and will be instrumental in driving disciplined, efficient growth. On October 1, Dr. Tony Jarc joined us in the newly created role of Chief Product and AI Officer.
Tony spent more than 15 years at Intuitive Surgical, where he built the global AI organization from the ground up, and he will lead the development of our next-generation technology platform, surgeon UI/UX, and personalized spine surgery procedures. Together, this team brings large-scale experience to drive the next phase of Carlsmed's growth. Operationally, we continue to demonstrate the efficiencies of our capital-light, digital-first business model. Our proprietary digital platform enables us to provide patient-specific and surgeon-specific preoperative 3D plans, personalized implants, and single-use instruments directly to the hospital. Without the significant capital investments required by traditional medtech companies, like surgical trays and stock implants, we can focus on patient-centric innovation in partnership with surgeons and hospitals to execute on our mission to improve patient outcomes.
With our deep focus on technology and operational excellence, we can consistently deliver aprevo surgical kits to the hospital in about a week after surgeon approval of the plan. We've achieved approximately 140 basis points of quarterly gross margin expansion year-over-year. Shifting to our commercial performance during the third quarter, our lumbar fusion franchise represented 88% of our revenue. We continue to grow the lumbar franchise rapidly, and we believe that we're still in the early innings, with an estimated 445,000 lumbar fusion procedures performed every year in the U.S. Clinical outcomes data remains core to our value proposition for surgeons and hospitals. Published data on over 500 aprevo patients has demonstrated improved surgical outcomes in both degenerative disc disease and adult spinal deformity. Most recently, at the SMISS Annual Forum in September, investigators presented two-year data on 378 lumbar fusion patients with low vertebral bone density.
Patients treated with aprevo had a two-year reoperation rate of approximately 6%, representing an 80% reduction in short fusions and an 85% reduction in long fusions compared to published literature in similar patient populations based on unadjusted cross-study comparisons. We believe this data is meaningful, as this patient population represents nearly 80% of spine surgery patients over age 50. On reimbursement, the CMS FY 2027 Inpatient Prospective Payment System, or IPPS, final rule went into place on October 1, 2026. The final rule consolidated the 11 MS-DRG codes previously applicable to aprevo inpatient lumbar procedures into three new codes, 523, 524, and 525. This new reimbursement structure simplifies coding and enhances reimbursement for hospitals providing the aprevo inpatient lumbar procedure, which we believe will broaden patient access.
We have invested in our strategic accounts team over the past few quarters to drive awareness and education of this important change, with the goal of accelerating hospital approval of aprevo. Finally, we continue to drive patient-centric innovation within our lumbar portfolio, and we are thrilled to announce the commercial launch of our aprevo posterior bilateral procedure in mid-October. Our newest procedure offering further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion. Feedback from surgeons during our limited market evaluation suggests that this procedure has the ability to achieve targeted disc and regional alignment with double the endplate coverage as compared to stock devices. This expansion of the lumbar procedure addresses an estimated 30,000 procedures, or approximately 7% of total lumbar fusions performed annually in the U.S. In our cervical business, surgeon reception and utilization has grown ahead of expectations post-launch.
With an estimated 370,000 cervical fusion procedures performed annually in the U.S., we are already driving impressive momentum of aprevo Cervical within this market as further extension of our technology platform. The aprevo Cervical procedure is designed to provide precise implant fit with maximized endplate coverage, which we believe has the potential to benefit patients who have a higher risk of reoperation, including those receiving more than two fused levels, patients with malalignment, and patients with low vertebral bone density, such as osteoporosis and osteopenia, conditions that collectively impact nearly 80% of patients. Approximately 80% of spine surgeons perform both lumbar and cervical fusions, with about 20% of new surgeon users starting with cervical only.
Our planned multicenter aprevo Cervical Effectiveness, or ACE Registry, will collect real-world evidence from patients treated with aprevo Cervical at six months, one year, and two-year time points, and we remain on track to commence enrollment this quarter. To expand our cervical franchise, we are also looking forward to commercially launching our FDA-cleared cervical plating system within the coming weeks. With the full launch of corra Personalized ACDF Plates, surgeons will have the flexibility to perform a personalized cervical procedure with standalone fixation, personalized multi-level fixation, or segmental fixation, with the goal of maintaining alignment as planned pre-operatively and delivered with the aprevo interbody device. Approximately 60% of cervical ACDF procedures in the U.S. utilize fixation plates, so we see this as having the potential to deepen utilization inside our current user base and accelerate new surgeon adoption with the cervical platform in 2027 and beyond.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
